Skip to main content

Table 2 Disease flares before and after TCZ initiation

From: Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations

  Total patients, N = 60
Before TCZ initiation After TCZ initiation
Follow-up time, median (IQR), years 0.6 (0.2–1.6) 0.6 (0.3–1.5)
Rate of flares per year*
 Rate (95% CI) 1.4 (1.0–2.1) 0.6 (0.3–1.0)
 Rate ratio (95% CI)   0.4 (0.3–0.6)
p value   0.0001
Patients with ≥ 1 flare, n (%) 43 (71.7) 18 (30.0)
 1 flare 19 (31.7) 11 (18.3)
 2 flares 11 (18.3) 3 (5.0)
 3 flares 4 (6.7) 3 (5.0)
 ≥ 4 flares 9 (15.0) 1 (1.7)
Total no. of flares 102 37
 With visual manifestations, n (%) 15 (14.7) 3 (8.1)
 With PMR symptoms, n (%) 57 (55.9) 21 (56.8)
  1. GCA giant cell arteritis, IQR interquartile range, PMR polymyalgia rheumatica, TCZ tocilizumab
  2. *Rates were estimated from a Poisson regression model with ongoing treatment (TCZ and prednisone combinations), age, smoking history, and new or relapsing GCA as covariates, and random patient effect
  3. Symptoms were after GCA diagnosis. Percentage of flares is out of the total number of flares